References

Global incidence and mortality of severe fungal disease

10.1016/s1473-3099(23)00692-8 · 2024 · External reference

Editorial: the World Health Organization (WHO) fungal priority pathogens list in response to emerging fungal pathogens during the COVID-19 pandemic

10.12659/msm.939088 · 2022 · External reference

COVID-19-associated fungal infections: An urgent need for alternative therapeutic approach?

10.3389/fmicb.2022.919501 · 2022 · External reference

Climate change: Shifting boundaries of fungal disease in Europe and beyond

10.1136/thorax-2024-222168 · 2025 · External reference

Interconnected worlds: A comprehensive review of fungal defenses, antimicrobial resistance, and their evolutionary dynamics

10.3897/imafungus.17.171995 · 2026 · External reference

Differentiation of Pneumocystis jirovecii pneumonia from colonization: A clinical decision framework incorporating risk stratification and next-generation sequencing thresholds

10.1186/s12879-025-11235-4 · 2025 · External reference

Novel model to predict risk of invasive fungal infection and fungal prophylaxis timing

10.1128/spectrum.02958-24 · 2025 · External reference

Fungal drug response and antimicrobial resistance

10.3390/jof9050565 · 2023 · External reference

The Lancet Infectious Diseases: An exciting time for antifungal therapy

10.1016/s1473-3099(23)00380-8 · 2023 · External reference

Antifungal pipeline

10.3389/fcimb.2021.732223 · 2021 · External reference

Liposomal amphotericin B: A review of its use as empirical therapy in febrile neutropenia and in the treatment of invasive fungal infections

10.2165/00003495-200969030-00010 · 2009 · External reference

Fungal lanosterol 14α-demethylase: A target for next-generation antifungal design

10.1016/j.bbapap.2019.02.008 · 2020 · External reference

Fungal resistance to echinocandins and the MDR phenomenon in Candida glabrata

10.3390/jof4030105 · 2018 · External reference

Resistance of Candida to azoles and echinocandins worldwide

10.1016/j.cmi.2019.03.028 · 2019 · External reference

5-flucytosine longitudinal antifungal susceptibility testing of Cryptococcus neoformans: A substudy of the EnACT trial testing oral amphotericin

10.1093/ofid/ofad596 · 2023 · External reference

Emerging drugs and vaccines for candidemia

10.1111/myc.12265 · 2014 · External reference

Candida auris genetics and emergence

10.1146/annurev-micro-032521-015858 · 2023 · External reference

Unresolved reference

External reference

New antifungal strategies and drug development against WHO critical priority fungal pathogens

10.3389/fcimb.2025.1662442 · 2025 · External reference

The antifungal pipeline: fosmanogepix, ibrexafungerp, olorofim, opelconazole, and rezafungin

10.1007/s40265-021-01611-0 · 2021 · External reference

Antimicrobial activity of manogepix, a first-in-class antifungal, and comparator agents tested against contemporary invasive fungal isolates from an international surveillance programme (2018-2019)

10.1016/j.jgar.2021.04.012 · 2021 · External reference

Efficacy of oral E1210, a new broad-spectrum antifungal with a novel mechanism of action, in murine models of candidiasis, aspergillosis, and fusariosis

10.1128/aac.00366-11 · 2011 · External reference

Pharmacodynamics, mechanisms of action and resistance, and spectrum of activity of new antifungal agents

10.3390/jof8080857 · 2022 · External reference

Safety and pharmacokinetics of intravenous and oral fosmanogepix, a first-in-class antifungal agent, in healthy volunteers

10.1128/aac.01623-22 · 2023 · External reference

Fosmanogepix for the treatment of invasive mold diseases caused by Aspergillus species and rare molds: A phase 2, open-label study (AEGIS)

10.1093/cid/ciaf185 · 2025 · External reference

Medicinal genetics approach towards identifying the molecular target of a novel inhibitor of fungal cell wall assembly

10.1046/j.1365-2958.2003.03481.x · 2003 · External reference

GWT1 gene is required for inositol acylation of glycosylphosphatidylinositol anchors in yeast

10.1074/jbc.m301044200 · 2003 · External reference

E1210, a new broad-spectrum antifungal, suppresses Candida albicans hyphal growth through inhibition of glycosylphosphatidylinositol biosynthesis

10.1128/aac.00731-11 · 2012 · External reference

In vitro activity of APX2041, a new Gwt1 inhibitor, and in vivo efficacy of the prodrug APX2104 against Aspergillus fumigatus

10.1128/aac.00682-21 · 2021 · External reference

10.1021/id5000212 · 2015 · Admitted local publication

Calcineurin inhibitors synergize with manogepix to kill diverse human fungal pathogens

10.3390/jof8101102 · 2022 · External reference

New perspectives on antimicrobial agents: Fosmanogepix

10.1128/aac.00324-26 · 2026 · External reference

Rho2-dependent cell wall remodeling boosts the fungistatic activity of manogepix against Aspergillus fumigatus

10.1016/j.tcsw.2025.100166 · 2025 · External reference

The wound microbiota: Microbial mechanisms of impaired wound healing and infection

10.1038/s41579-024-01035-z · 2024 · External reference

Antibiofilm activity of manogepix, ibrexafungerp, amphotericin B, rezafungin, and caspofungin against Candida spp. biofilms of reference and clinical strains

10.1128/aac.00137-25 · 2025 · External reference

Evaluation of resistance development to the Gwt1 inhibitor manogepix (APX001A) in Candida species

10.1128/aac.01387-19 · 2019 · External reference

Structural insights into the inhibition mechanism of fungal GWT1 by manogepix

10.1038/s41467-024-53512-x · 2024 · External reference

Enhanced efflux pump expression in Candida mutants results in decreased manogepix susceptibility

10.1128/aac.00261-20 · 2020 · External reference

TAC1b mutation in Candida auris decreases manogepix susceptibility owing to increased CDR1 expression

10.1128/aac.01508-24 · 2025 · External reference

Mutations in transcription factors that confer fluconazole resistance also confer reduced susceptibility to manogepix in Candida auris (Candidozyma auris), Candida albicans, Candida parapsilosis, and Candida glabrata (Nakaseomyces glabratus)

10.1128/aac.00680-25 · 2025 · External reference

Calcium-calmodulin-calcineurin signaling: A globally conserved virulence cascade in eukaryotic microbial pathogens

10.1016/j.chom.2019.08.004 · 2019 · External reference

Fungal cell wall: Emerging antifungals and drug resistance

10.3389/fmicb.2019.02573 · 2019 · External reference

Echinocandin tolerance and persistence in vitro are regulated by calcineurin signaling in Candida glabrata

10.1128/mbio.02546-25 · 2026 · External reference

Fosmanogepix: the novel anti-fungal agent's comprehensive review of in vitro, in vivo, and current insights from advancing clinical trials

10.7759/cureus.59210 · 2024 · External reference

Manogepix (APX001A) displays potent in vitro activity against human pathogenic yeast, but with an unexpected correlation to fluconazole MICs

10.1128/aac.00429-20 · 2020 · External reference

APX001A in vitro activity against contemporary blood isolates and Candida auris determined by the EUCAST reference method

10.1128/aac.01225-18 · 2018 · External reference

In vitro activity of a novel broad-spectrum antifungal, E1210, tested against Candida spp. as determined by CLSI broth microdilution method

10.1016/j.diagmicrobio.2011.05.001 · 2011 · External reference

In vitro activity of APX001A (Manogepix) and comparator agents against 1,706 fungal Isolates collected during an international surveillance program in 2017

10.1128/aac.00840-19 · 2019 · External reference

The investigational agent E1210 is effective in treatment of experimental invasive candidiasis caused by resistant Candida albicans

10.1128/aac.03944-14 · 2015 · External reference

In vitro activity of E1210, a novel antifungal, against clinically important yeasts and molds

10.1128/aac.00291-11 · 2011 · External reference

Pre-clinical development of antifungal susceptibility test methods for the testing of the novel antifungal agent E1210 versus Candida: Comparison of CLSI and European committee on antimicrobial susceptibility testing methods

10.1093/jac/dkr342 · 2011 · External reference

In vitro activity of manogepix and comparators against infrequently encountered yeast and mold isolates from the SENTRY Surveillance Program (2017-2022)

10.1128/aac.01132-23 · 2024 · External reference

New treatment options for critically important WHO fungal priority pathogens

10.1016/j.cmi.2024.03.006 · 2025 · External reference

In vitro and in vivo evaluation of APX001A/APX001 and other Gwt1 inhibitors against Cryptococcus

10.1128/aac.00523-18 · 2018 · External reference

2043. In vitro activity of manogepix against 2,810 fungal isolates from the SENTRY surveillance program (2020-2021) stratified by infection type

2022 · External reference

In vitro activity of APX001A against rare moulds using EUCAST and CLSI methodologies

10.1093/jac/dkz022 · 2019 · External reference

In vitro antifungal activity of manogepix and other antifungal agents against South African Candida auris isolates from bloodstream infections

10.1128/spectrum.01717-21 · 2022 · External reference

Activities of E1210 and comparator agents tested by CLSI and EUCAST broth microdilution methods against Fusarium and Scedosporium species identified using molecular methods

10.1128/aac.05414-11 · 2012 · External reference

In vitro activity of manogepix against multidrug-resistant and panresistant Candida auris from the New York outbreak

10.1128/aac.01124-20 · 2020 · External reference

Manogepix (APX001A) in vitro activity against Candida auris: Head-to-head comparison of EUCAST and CLSI MICs

10.1128/aac.00656-20 · 2020 · External reference

Antifungal susceptibility surveillance of clinical moulds to olorofim, manogepix, amphotericin B, triazoles and echinocandins at 10 tertiary hospitals in China (2019-24)

10.1093/jac/dkag016 · 2026 · External reference

In vitro activity of manogepix (APX001A) and comparators against contemporary molds: MEC comparison and preliminary experience with colorimetric MIC determination

10.1128/aac.00730-20 · 2020 · External reference

Environmental hot spots and resistance-associated application practices for azole-resistant Aspergillus fumigatus, Denmark, 2020-2023

10.3201/eid3008.240096 · 2024 · External reference

Manogepix, the active moiety of the investigational agent fosmanogepix, demonstrates in vitro activity against members of the Fusarium oxysporum and Fusarium solani species complexes

10.1128/aac.02343-20 · 2021 · External reference

Fosmanogepix (APX001) is effective in the treatment of pulmonary murine mucormycosis due to Rhizopus arrhizus

10.1128/aac.00178-20 · 2020 · External reference

In vitro and in vivo evaluation of the antifungal activity of APX001A/APX001 against Candida auris

10.1128/aac.02319-17 · 2018 · External reference

Efficacy of delayed therapy with fosmanogepix (APX001) in a murine model of Candida auris invasive candidiasis

10.1128/aac.01120-19 · 2019 · External reference

APX001 is effective in the treatment of murine invasive pulmonary aspergillosis

10.1128/aac.01713-18 · 2019 · External reference

APX001 and other Gwt1 inhibitor prodrugs are effective in experimental Coccidioides immitis pneumonia

10.1128/aac.01715-18 · 2019 · External reference

Fosmanogepix (APX001) is effective in the treatment of immunocompromised mice infected with invasive pulmonary scedosporiosis or disseminated fusariosis

10.1128/aac.01735-19 · 2020 · External reference

The combination treatment of fosmanogepix and liposomal amphotericin B is superior to monotherapy in treating experimental invasive mold infections

10.1128/aac.00380-22 · 2022 · External reference

First-in-human study to assess safety, tolerability and pharmacokinetics of APX001 administered by intravenous infusion to healthy subjects

2017 · External reference

Phase 1 study to assess safety, tolerability and pharmacokinetics of single and multiple oral doses of APX001 and to investigate the effect of food on APX001 bioavailability

2017 · External reference

Phase 1b safety and pharmacokinetics of intravenous and oral fosmanogepix in patients with acute myeloid leukaemia and neutropenia

10.1093/jac/dkad269 · 2023 · External reference

Clinical efficacy and safety of a novel antifungal, fosmanogepix, in patients with candidemia caused by Candida auris: Results from a phase 2 trial

10.1128/aac.01419-22 · 2023 · External reference

Clinical safety and efficacy of novel antifungal, fosmanogepix, for the treatment of candidaemia: Results from a phase 2 trial

10.1093/jac/dkad256 · 2023 · External reference

Fosmanogepix treatment for coccidioidomycosis under an expanded access program

10.1093/cid/ciag271 · 2026 · External reference

The importance of antimicrobial resistance in medical mycology

10.1038/s41467-022-32249-5 · 2022 · External reference

Heightened efficacy of anidulafungin when used in combination with manogepix or 5-flucytosine against Candida auris in vitro

10.1128/aac.01645-22 · 2023 · External reference

The combination of manogepix and itraconazole is synergistic and inhibits the growth of Madurella mycetomatis in vitro but not in vivo

10.1093/mmy/myad118 · 2023 · External reference

Novel approaches in the management of mucormycosis

10.1007/s12281-023-00463-3 · 2023 · External reference

Efficacy and pharmacokinetics of fosmanogepix (APX001) in the treatment of Candida endophthalmitis and hematogenous meningoencephalitis in nonneutropenic rabbits

10.1128/aac.01795-20 · 2021 · External reference

Antifungal agents in the 21st century: advances, challenges, and future perspectives

10.3390/idr17040091 · 2025 · External reference

Antifungal chemotherapies and immunotherapies for the future

10.1111/pim.12960 · 2023 · External reference

Aminopyrifen, a novel 2-aminonicotinate fungicide with a unique effect and broad-spectrum activity against plant pathogenic fungi

10.1584/jpestics.d20-094 · 2021 · External reference

Understanding inflammatory bowel disease: an integrative framework of microbiome, metabolome, and immunological biomarkers

2025 · External reference

Activity of novel antifungal compound APX001A against a large collection of Candida auris

10.1093/jac/dky302 · 2018 · External reference

In vitro activity of a novel broad-spectrum antifungal, E1210, tested against Aspergillus spp. determined by CLSI and EUCAST broth microdilution methods

10.1128/aac.00570-11 · 2011 · External reference

In vivo pharmacokinetics and pharmacodynamics of APX001 against Candida spp. in a neutropenic disseminated Candidiasis mouse model

10.1128/aac.02542-17 · 2018 · External reference

Significantly improved pharmacokinetics enhances in vivo efficacy of APX001 against echinocandin- and multidrug resistant Candida isolates in a mouse model of invasive Candidiasis

10.1128/aac.00425-18 · 2018 · External reference

APX001 pharmacokinetic/pharmacodynamic target determination against Aspergillus fumigatus in an in vivo model of invasive pulmonary Aspergillosis

10.1128/aac.02372-18 · 2019 · External reference

Galactomannan is a biomarker of Fosmanogepix (APX001) efficacy in treating experimental invasive pulmonary Aspergillosis

10.1128/aac.01966-19 · 2019 · External reference